MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA (lurasidone HCl) . These data were presented at the 165th Annual Meeting of the American Psychiatric Association in Philadelphia, Pennsylvania.
